Substituted annulated pyrimidines and triazines, and use thereof

Abstract

The present application relates to novel substituted fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

1 . A compound of the formula (I) 
       
         
           
           
               
               
           
         
         in which 
         A represents nitrogen or CR 5 ,
 where 
 R 5  represents hydrogen, deuterium, chlorine, iodine, difluoromethyl, trifluoromethyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl, cyclopropyl, cyclobutyl, phenyl or 5- or 6-membered heteroaryl which is attached via carbon,
 in which (C 1 -C 6 )-alkyl, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl, phenyl and 5- or 6-membered heteroaryl which is attached via carbon may each be substituted by 1 to 3 substituents selected independently of one another from the group comprising cyano, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 4 )-alkyl, difluoromethoxy, trifluoromethoxy, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkoxycarbonyl, hydroxy, hydroxycarbonyl, cyclopropyl, cyclobutyl and —(C═O)—NR 21 R 22 , 
 in which 
 (C 1 -C 6 )-alkyl may be substituted by an —NR 13 R 14  group, 
 in which 
 R 13  represents hydrogen, methyl or ethyl,
 in which 
 ethyl may be substituted by 1 to 3 fluorine substituents, 
 
 R 14  represents hydrogen, (C 1 -C 4 )-alkyl, —(C═O)—R 15  or —S(O) 2 —R 16 ,
 in which 
 (C 1 -C 4 )-alkyl may be substituted by 1 to 3 fluorine substituents, 
 and in which 
 R 15  represents (C 1 -C 4 )-alkyl or (C 3 -C 5 )-cycloalkyl, 
 R 16  represents (C 1 -C 4 )-alkyl or (C 3 -C 5 )-cycloalkyl, 
 
 or 
 R 13  and R 14  together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle,
 in which the 4- to 7-membered heterocycle for its part may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of trifluoromethyl, (C 1 -C 4 )-alkyl, hydroxy and oxo, 
 
 and in which 
 R 21  represents hydrogen or (C 1 -C 4 )-alkyl, 
 R 22  represents hydrogen or (C 1 -C 4 )-alkyl,
 in which (C 1 -C 4 )-alkyl for its part may in each case be substituted by hydroxy or fluorine, 
 
 or 
 R 21  and R 22  together with the atom to which they are attached form a 4- to 7-membered heterocycle, 
 
 
         L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group
 where 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m represents a number 0, 1 or 2, 
 R 6A  represents hydrogen, fluorine, (C 1 -C 4 )-alkyl, hydroxy or amino,
 in which (C 1 -C 4 )-alkyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, hydroxy, (C 1 -C 4 )-alkoxy, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl and amino, 
 
 R 6B  represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, cyano, (C 3 -C 7 )-cycloalkyl, difluoromethoxy, trifluoromethoxy or a group of the formula -M-R 12 ,
 in which (C 1 -C 6 )-alkyl may be substituted by 1 to 3 substituents selected independently of one another from the group consisting of (C 1 -C 4 )-alkoxy, fluorine, cyano, trifluoromethyl, (C 3 -C 7 )-cycloalkyl, difluoromethoxy and trifluoromethoxy, 
 in which (C 1 -C 4 )-alkoxy may be substituted by phenyl, 
 and in which 
 M represents a bond or (C 1 -C 4 )-alkanediyl, 
 R 12  represents —(C═O) r —OR 8 , —(C═O) r —NR 8 R 9 , —C(═S)—NR 8 R 9 , —NR 8 —(C═O)—R 11 , —NR 8 —(C═O)—OR 11 , —NR 8 —(C═O)—NR 9 R 10 , —NR 8 —SO 2 —NR 9 R 10 , —NR 8 —SO 2 —R 11 , —S(O) s —R 11 , —SO 2 —NR 8 R 9 , 4- to 7-membered heterocyclyl, phenyl, benzyl or 5- or 6-membered heteroaryl,
 in which 
 r represents the number 0 or 1, 
 s represents the number 0, 1 or 2, 
 R 8 , R 9  and R 10  independently of one another each represent hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 8 )-cycloalkyl, 4- to 7-membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl, 
 or 
 R 8  and R 9  together with the atom(s) to which they are respectively attached form a 4- to 7-membered heterocycle, 
  in which the 4- to 7-membered heterocycle for its part may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of cyano, trifluoromethyl, (C 1 -C 6 )-alkyl, hydroxy, oxo, (C 1 -C 6 )-alkoxy, trifluoromethoxy, (C 1 -C 6 )-alkoxycarbonyl, amino, mono-(C 1 -C 6 )-alkylamino and di-(C 1 -C 6 )-alkylamino, 
 or 
 R 9  and R 10  together with the atom(s) to which they are respectively attached form a 4- to 7-membered heterocycle, 
  in which the 4- to 7-membered heterocycle for its part may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of cyano, trifluoromethyl, (C 1 -C 6 )-alkyl, hydroxy, oxo, (C 1 -C 6 )-alkoxy, trifluoromethoxy, (C 1 -C 6 )-alkoxycarbonyl, amino, mono-(C 1 -C 6 )-alkylamino and di-(C 1 -C 6 )-alkylamino, 
 R 11  represents (C 1 -C 6 )-alkyl or (C 3 -C 7 )-cycloalkyl, 
 or 
 R 8  and R 11  together with the atom(s) to which they are respectively attached form a 4- to 7-membered heterocycle, 
  in which the 4- to 7-membered heterocycle for its part may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of cyano, trifluoromethyl, (C 1 -C 6 )-alkyl, hydroxy, oxo, (C 1 -C 6 )-alkoxy, trifluoromethoxy, (C 1 -C 6 )-alkoxycarbonyl, amino, mono-(C 1 -C 6 )-alkylamino and di-(C 1 -C 6 )-alkylamino, 
 and 
 in which 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl for their part may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of halogen, cyano, difluoromethyl, trifluoromethyl, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, hydroxy, oxo, thioxo and (C 1 -C 4 )-alkoxy, 
 and 
 in which the aforementioned (C 1 -C 4 )-alkyl, (C 1 -C 6 )-alkyl, (C 3 -C 8 )-cycloalkyl and 4- to 7-membered heterocyclyl groups, unless stated otherwise, may each independently of one another additionally be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, hydroxy, difluoromethoxy, trifluoromethoxy, (C 1 -C 4 )-alkoxy, hydroxycarbonyl, (C 1 -C 4 )-alkoxycarbonyl, amino, phenyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl, 
 
 
 or 
 R 6A  and R 6B  together with the carbon atom to which they are attached form a (C 2 -C 4 )-alkenyl group, an oxo group, a 3- to 6-membered carbocycle or a 4- to 7-membered heterocycle,
 in which the 3- to 6-membered carbocycle and the 4- to 7-membered heterocycle may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine and (C 1 -C 4 )-alkyl, 
 
 R 7A  represents hydrogen, fluorine, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxycarbonyl or hydroxy, 
 R 7B  represents hydrogen, fluorine, (C 1 -C 4 )-alkyl or trifluoromethyl, 
 
         R 1  represents hydrogen, fluorine, cyano, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, trifluoromethyl, difluoromethyl, (C 3 -C 6 )-cycloalkyl or halogen, 
         R 2  represents benzyl, 3,3,3-trifluoroprop-1-yl, 4,4,4-trifluorobut-1-yl or 3,3,4,4,4-pentafluorobut-1-yl,
 where benzyl is substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, chlorine, (C 1 -C 4 )-alkyl, cyclopropyl and (C 1 -C 4 )-alkoxy, 
 
         R 3  represents hydrogen, cyano, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, trifluoromethyl, difluoromethyl or (C 3 -C 6 )-cycloalkyl, 
         R 4  represents hydrogen, cyano, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, trifluoromethyl, difluoromethyl or (C 3 -C 6 )-cycloalkyl, 
         or an N-oxides, salt or salt of an N-oxide thereof. 
       
     
     
         2 . The compound of  claim 1 , wherein
 A represents nitrogen or CR 5 ,
 where 
 R 5  represents hydrogen, deuterium, chlorine, iodine, difluoromethyl, trifluoromethyl, (C 1 -C 6 )-alkyl, vinyl, allyl, ethynyl, cyclopropyl, cyclobutyl, phenyl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyrrol-5-yl, 1,3-thiazol-5-yl, 1,3,4-thiadiazol-5-yl or pyridyl,
 in which (C 1 -C 6 )-alkyl, vinyl, allyl, ethynyl, phenyl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyrrol-5-yl, 1,3-thiazol-5-yl, 1,3,4-thiadiazol-5-yl and pyridyl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine, cyano, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl, methoxy, ethoxy, hydroxy, (C 1 -C 4 )-alkoxycarbonyl, hydroxycarbonyl, cyclopropyl, cyclobutyl and —(C═O)—NR 21 R 22 , 
 in which 
 (C 1 -C 6 )-alkyl may be substituted by an —NR 13 R 14  group, 
 in which 
 R 13  represents hydrogen, methyl or ethyl,
 in which 
 ethyl may be substituted by 1 to 3 fluorine substituents, 
 
 R 14  represents hydrogen, (C 1 -C 4 )-alkyl, —(C═O)—R 15  or —S(O) 2 —R 16 ,
 in which 
 (C 1 -C 4 )-alkyl may be substituted by 1 to 3 fluorine substituents, 
 and in which 
 R 15  represents (C 1 -C 4 )-alkyl or (C 3 -C 5 )-cycloalkyl, 
 R 16  represents (C 1 -C 4 )-alkyl or (C 3 -C 5 )-cycloalkyl, 
 
 or 
 R 13  and R 14  together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle,
 in which the 4- to 6-membered heterocycle for its part may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of trifluoromethyl, (C 1 -C 4 )-alkyl and oxo, 
 
 and in which 
 R 21  represents hydrogen or (C 1 -C 4 )-alkyl, 
 R 22  represents hydrogen or (C 1 -C 4 )-alkyl,
 in which (C 1 -C 4 )-alkyl for its part may in each case be substituted by hydroxy or fluorine, 
 
 or 
 R 21  and R 22  together with the atom to which they are attached form a 4- to 7-membered heterocycle, 
 
   L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group
 where 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m represents a number 0 or 1, 
 R 6A  represents hydrogen, fluorine, methyl, ethyl, hydroxy or amino, 
 R 6B  represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 4 )-alkyl, (C 2 -C 6 )-alkenyl, cyano, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-R 12 ,
 in which (C 1 -C 4 )-alkyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of (C 1 -C 4 )-alkoxy, fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy and trifluoromethoxy, 
 in which (C 1 -C 4 )-alkoxy may be substituted by phenyl, 
 and in which 
 M represents a bond, methylene, ethane-1,2-diyl or propane-1,3-diyl, 
 R 12  represents —(C═O) r —OR 8 , —(C═O) r —NR 8 R 9 , —C(═S)—NR 8 R 9 , —NR 8 —(C═O)—OR 11 , —NR 8 —(C═O)—NR 9 R 10 , oxadiazolonyl, oxadiazolothionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl or pyrazinyl,
 in which 
 r represents the number 0 or 1, 
 R 8  and R 9  independently of one another each represent hydrogen, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl or pyridyl, 
  in which methyl, ethyl and isopropyl may additionally be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl and amino, 
 R 11  is methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, 
 and 
 in which oxadiazolonyl, oxadiazolethionyl, phenyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl and pyrazinyl for their part may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclobutylmethyl, hydroxy, methoxy and ethoxy, 
 
 
 or 
 R 6A  and R 6B  together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl or tetrahydropyranyl ring,
 in which the cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl and tetrahydropyranyl ring may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine and methyl, 
 
 R 7A  represents hydrogen, fluorine, methyl, ethyl or hydroxy, 
 R 7B  represents hydrogen, fluorine, methyl, ethyl, trifluoromethyl or (C 1 -C 4 )-alkoxycarbonyl, 
   R 1  represents hydrogen or fluorine,   R 2  represents benzyl, 3,3,3-trifluoroprop-1-yl, 4,4,4-trifluorobut-1-yl or 3,3,4,4,4-pentafluorobut-1-yl,
 where benzyl is substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, methyl and methoxy, 
   R 3  represents hydrogen, methyl or trifluoromethyl,   R 4  represents hydrogen,   or a salt thereof.   
     
     
         3 . The compound  claim 1 , wherein
 A represents nitrogen or CR 5 ,
 where 
 R 5  represents hydrogen, (C 1 -C 6 )-alkyl, vinyl, ethynyl, pyrazol-5-yl, pyrrol-5-yl, 1,3-thiazol-5-yl, 1,3,4-thiadiazol-5-yl or pyridyl,
 in which (C 1 -C 6 )-alkyl, vinyl and ethynyl may be substituted by 1 methyl, trifluoromethyl, methoxy, ethoxy, hydroxy, methoxycarbonyl, ethoxycarbonyl, cyclopropyl or —(C═O)—NR 21 R 22  substituent, 
 in which pyridyl may be substituted by 1 methoxy substituent, 
 in which 1,3-thiazol-5-yl and 1,3,4-thiadiazol-5-yl independently of one another may be substituted by 1 or 2 substituents selected from the group consisting of methyl and ethyl, 
 in which pyrrol-5-yl may be substituted by methyl and cyano, 
 and in which 
 R 21  represents hydrogen or (C 1 -C 4 )-alkyl, 
 R 22  represents hydrogen or (C 1 -C 4 )-alkyl, 
 or 
 represents a —CH 2 —NR 13 R 14  or —CH 2 —CH 2 —NR 13 R 14  group, 
 in which 
 R 13  represents hydrogen, methyl or ethyl, 
 R 14  represents hydrogen, methyl, ethyl, —(C═O)—R 15  or —S(O) 2 —R 16 ,
 in which 
 ethyl may be substituted by 1 to 3 fluorine substituents, 
 and in which 
 R 15  represents methyl, ethyl or cyclopropyl, 
 R 16  represents methyl, ethyl or cyclopropyl, 
 
 or 
 R 13  and R 14  together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle,
 in which the 5- or 6-membered heterocycle for its part may be substituted by oxo, 
 
 
 L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group
 where 
 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m is a number 0, 
 R 6A  represents hydrogen, methyl, ethyl, hydroxy or amino, 
 R 6B  represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, 1,1,2,2,2-pentafluoroeth-1-yl, methyl, ethyl, allyl, but-3-en-1-yl or a group of the formula -M-R 12 ,
 in which methyl and ethyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl, difluoromethoxy, trifluoromethoxy, methoxy and ethoxy,
 in which methoxy and ethoxy may be substituted by phenyl, 
 
 and in which 
 M represents a bond, 
 R 12  represents —(C═O) r —NR 8 R 9  or 1,3,4-thiadiazol-5-yl,
 in which 
 r represents the number 1, 
 R 8  and R 9  independently of one another each represent hydrogen or cyclopropyl, 
 and 
 in which 1,3,4-thiadiazol-5-yl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, methyl and ethyl, 
 
 
 or 
 R 6A  and R 6B  together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl or tetrahydropyranyl ring,
 in which the cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl and tetrahydropyranyl ring may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine and methyl, 
 
   R 1  represents hydrogen or fluorine,   R 2  is a group of the formula   
       
         
           
           
               
               
           
         
         where 
         * is the point of attachment to the pyrazolopyridine, 
         and
 R 17 , R 18 , R 19  and R 20  independently of one another represent hydrogen, fluorine, methyl or methoxy, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is different from hydrogen, 
 and 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is hydrogen, 
 
         or 
         R 2  represents 3,3,3-trifluoroprop-1-yl or 3,3,4,4,4-pentafluorobut-1-yl, 
         R 3  represents hydrogen, methyl or trifluoromethyl, 
         R 4  represents hydrogen, 
         or a salt thereof. 
       
     
     
         4 . The compound of  claim 1 , wherein
 A represents nitrogen or CR 5 ,
 where 
 R 5  represents hydrogen, methyl, ethyl, propyl, vinyl, ethynyl, pyrazol-5-yl, pyrrol-5-yl, 1,3-thiazol-5-yl, 1,3,4-thiadiazol-5-yl or pyridyl,
 in which methyl, ethyl, propyl, vinyl and ethynyl may be substituted by 1 methyl, trifluoromethyl, methoxy, ethoxy, hydroxy, methoxycarbonyl, ethoxycarbonyl, cyclopropyl or —(C═O)—NR 21 R 22  substituent, 
 in which pyridyl may be substituted by 1 methoxy substituent, 
 in which 1,3-thiazol-5-yl and 1,3,4-thiadiazol-5-yl independently of one another may be substituted by 1 or 2 substituents selected from the group consisting of methyl and ethyl, 
 in which pyrrol-5-yl may be substituted by methyl and cyano, 
 and in which 
 R 21  represents hydrogen, 
 R 22  represents hydrogen, 
 or 
 represents a —CH 2 —NR 13 R 14  or —CH 2 —CH 2 —NR 13 R 14  group, 
 in which 
 R 13  represents hydrogen or methyl, 
 R 14  represents hydrogen, methyl, ethyl, —(C═O)—R 15  or —S(O) 2 —R 16 ,
 in which 
 ethyl may be substituted by 1 to 3 fluorine substituents, 
 and in which 
 R 15  represents methyl, ethyl or cyclopropyl, 
 R 16  represents methyl, ethyl or cyclopropyl, 
 
 or 
 R 13  and R 14  together with the nitrogen atom to which they are attached form a 5-membered heterocycle,
 in which the 5-membered heterocycle for its part may be substituted by oxo, 
 
 
 L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group,
 where 
 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m is a number 0, 
 R 6A  represents hydrogen, methyl, ethyl, hydroxy or amino, 
 R 6B  represents hydrogen, trifluoromethyl, 1,1,2,2,2-pentafluoroeth-1-yl, methyl, ethyl, allyl, but-3-en-1-yl or a group of the formula -M-R 12 ,
 in which methyl and ethyl may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, methoxy and ethoxy,
 in which methoxy and ethoxy may be substituted by phenyl, 
 
 and in which 
 M represents a bond, 
 R 12  represents —(C═O) r —NR 8 R 9  or thiadiazolyl,
 in which 
 r represents the number 1, 
 R 8  and R 9  independently of one another each represent hydrogen or cyclopropyl, 
 
 
 or 
 R 6A  and R 6B  together with the carbon atom to which they are attached form a cyclobutyl or cyclopentyl ring, 
   R 1  represents hydrogen or fluorine,   R 2  is a group of the formula   
       
         
           
           
               
               
           
         
         where 
         * is the point of attachment to the pyrazolopyridine, 
         and
 R 17 , R 18 , R 19  and R 20  independently of one another represent hydrogen, fluorine, methyl or methoxy, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is different from hydrogen, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is hydrogen, 
 and 
 with the proviso that in each case only one of the radicals R 17 , R 18 , R 19  or R 20  represents methyl or methoxy, 
 
         or 
         R 2  represents 3,3,3-trifluoroprop-1-yl or 3,3,4,4,4-pentafluorobut-1-yl, 
         R 3  represents hydrogen, methyl or trifluoromethyl, 
         R 4  represents hydrogen, 
         or a salt thereof. 
       
     
     
         5 . The compound of  claim 1 , wherein
 A represents nitrogen or CR 5 ,
 where 
 R 5  represents methyl or pyrazol-5-yl,
 in which methyl is substituted by an —NR 13 R 14  group, 
 in which 
 R 13  represents hydrogen, 
 R 14  represents hydrogen, methyl, ethyl or —S(O) 2 —R 16 ,
 in which 
 ethyl may be substituted by 1 to 3 fluorine substituents, 
 and in which 
 R 16  represents methyl or cyclopropyl, 
 
 or 
 R 13  and R 14  together with the nitrogen atom to which they are attached form a 5-membered heterocycle,
 in which the 5-membered heterocycle for its part may be substituted by oxo, 
 
 
 L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group,
 where 
 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m is a number 0, 
 R 6A  represents methyl, 
 R 6B  represents methyl, 
   R 1  represents hydrogen or fluorine,   R 2  is a group of the formula   
       
         
           
           
               
               
           
         
         where 
         * is the point of attachment to the pyrazolopyridine, 
         and
 R 17 , R 18 , R 19  and R 20  independently of one another represent hydrogen, fluorine, methyl or methoxy, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is different from hydrogen, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is hydrogen, 
 and 
 with the proviso that in each case only one of the radicals R 17 , R 18 , R 19  or R 20  represents methyl or methoxy, 
 
         R 3  represents hydrogen, methyl or trifluoromethyl, 
         R 4  represents hydrogen, 
         or a salt thereof. 
       
     
     
         6 . The compound of  claim 1 , wherein
 A represents nitrogen or CR 5 ,
 where 
 R 5  represents hydrogen, 
   L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group,
 where 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m represents a number 0, 
 R 6A  represents amino, 
 R 6B  represents hydrogen, fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl or a group of the formula -M-R 12 ,
 in which methyl and ethyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl, difluoromethoxy, trifluoromethoxy, methoxy and ethoxy, 
 and in which 
 M represents a bond, 
 R 12  represents —(C═O) r —NR 8 R 9 , phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl,
 in which 
 r represents the number 1, 
 R 8  and R 9  independently of one another each represent hydrogen or cyclopropyl, 
 and 
 in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and pyrimidinyl may each in turn be substituted by 1 or 2 substituents selected independently of one another from the group consisting of fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl, cyclopropylmethyl and cyclobutylmethyl, 
 
 
   R 1  represents hydrogen or fluorine,   R 2  is a group of the formula   
       
         
           
           
               
               
           
         
         where 
         * is the point of attachment to the pyrazolopyridine,
 and 
 R 17 , R 18 , R 19  and R 20  independently of one another represent hydrogen, fluorine, methyl or methoxy, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is different from hydrogen, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is hydrogen, 
 and 
 with the proviso that in each case only one of the radicals R 17 , R 18 , R 19  or R 20  represents methyl or methoxy, 
 
         R 3  represents hydrogen or methyl, 
         R 4  represents hydrogen, 
         or a salt thereof. 
       
     
     
         7 . The compound of  claim 1 , wherein
 A represents nitrogen or CR 5 ,
 where 
 R 5  represents hydrogen, 
   L represents a # 1 -CR 6A R 6B —(CR 7A R 7B ) m -# 2  group,
 where 
 # 1  is the point of attachment to the carbonyl group, 
 # 2  is the point of attachment to the pyrimidine or triazine ring, 
 m is a number 0, 
 R 6A  represents hydroxy, 
 R 6B  represents 2,2,2-trifluoroethyl, pentafluoroethyl or (C 1 -C 4 )-alkyl,
 in which (C 1 -C 4 )-alkyl is substituted by 1 substituent selected from the group consisting of (C 3 -C 7 )-cycloalkyl, difluoromethoxy, trifluoromethoxy and (C 1 -C 4 )-alkoxy, 
 
   R 1  represents hydrogen or fluorine,   R 2  is a group of the formula   
       
         
           
           
               
               
           
         
         where 
         * is the point of attachment to the pyrazolopyridine,
 and 
 R 17 , R 18 , R 19  and R 20  independently of one another represent hydrogen, fluorine, methyl or methoxy, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is different from hydrogen, 
 with the proviso that at least one of the radicals R 17 , R 18 , R 19  or R 20  is hydrogen, 
 and 
 with the proviso that in each case only one of the radicals R 17 , R 18 , R 19  or R 20  represents methyl or methoxy, 
 
         R 3  represents hydrogen or methyl, 
         R 4  represents hydrogen, 
         or a salt thereof. 
       
     
     
         8 . A compounds selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         9 . A process for preparing a compound of the formula (I) as defined in  claim 1 , comprising reacting a compound of the formula (II) 
       
         
           
           
               
               
           
         
         in which R 1 , R 2 , R 3  and R 4  each have the meanings given in  claim 1   
         [A] in an inert solvent in the presence of a suitable base with a compound of the formula (III) 
       
       
         
           
           
               
               
           
         
         
           in which L has the meaning given in  claim 1  and 
           T 1  represents (C 1 -C 4 )-alkyl, 
           to give a compound of the formula (IV) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3  and R 4  each have the meanings given above, 
           converting the compound of formula (IV) with isopentyl nitrite and a halogen equivalent into a compound of the formula (V) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3  and R 4  each have the meanings given above and 
           X 1  represents chlorine, bromine or iodine, 
           reacting the compound of formula (V) in an inert solvent, in the presence of a suitable transition metal catalyst, to give a compound of the formula (I-A) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3  and R 4  each have the meanings given above, 
         
         or 
         [B] reacting the compound of formula (II) in an inert solvent in the presence of a suitable base with a compound of the formula (VI) 
       
       
         
           
           
               
               
           
         
         
           in which L and R 5  each have the meanings given above and 
           T 3  represents (C 1 -C 4 )-alkyl, 
           to give a compound of the formula (VII) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4 , R 5  and T 3  each have the meanings given above, 
           converting the compound of formula (VII) with phosphoryl chloride into a compound of the formula (VIII) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4 , R 5  and T 3  each have the meanings given above, 
           converting the compound of formula (VIII) in an inert solvent into a corresponding azide compound and this is reduced directly to give a compound of the formula (IX) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4 , R 5  and T 3  each have the meanings given above, 
           optionally reacting the compound of formula (IX) in an inert solvent in the presence of a suitable base, to give a compound of the formula (I-B) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4 , R 5  and T 3  each have the meanings given above, 
         
         or 
         [C] reacting the compound of formula (II) in an inert solvent in the presence of a suitable base with hydrazine hydrate to give a compound of the formula (X) 
       
       
         
           
           
               
               
           
         
         
           in which R 1 , R 2 , R 3  and R 4  each have the meanings given above, 
           reacting the compound of formula (X) in an inert solvent with a compound of the formula (XI) 
         
       
       
         
           
           
               
               
           
         
         
           in which L has the meaning given above and 
           T 4  represents (C 1 -C 4 )-alkyl, 
           to give a compound of the formula (XII) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4  and T 4  each have the meanings given above, converting the compound of formula (XII) with phosphoryl chloride into a compound of the formula (XIII) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4  and T 4  each have the meanings given above, 
         
         reacting the compound of formula (XIII) directly with ammonia to give a compound of the formula (XIV) 
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4  and T 4  each have the meanings given above, 
           and cyclizing the compound of formula (XIV) in an inert solvent, optionally in the presence of a suitable base, to give a compound of the formula (I-C) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3  and R 4  each have the meanings given above, 
         
         or 
         [D] reacting the compound of the formula (V) in an inert solvent in the presence of a suitable transition metal catalyst with a compound of the formula (XV-A), (XV-B), (XV-C) or (XV-D) 
       
       
         
           
           
               
               
           
         
         
           in which 
           R 5A  in (XV-A) represents (C 2 -C 4 )-alkenyl or (C 2 -C 4 )-alkynyl, 
           R 5A  in (XV-B), (XV-C) and (XV-D) represents halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4 )-alkyl, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl, cyclopropyl, cyclobutyl, phenyl or 5- or 6-membered heteroaryl,
 in which (C 1 -C 4 )-alkyl, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl, phenyl and 5- or 6-membered heteroaryl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 4 )-alkyl, difluoromethoxy, trifluoromethoxy, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkoxycarbonyl, cyclopropyl and cyclobutyl, 
 
           T 2  is hydrogen or (C 1 -C 4 )-alkyl, or both R 11  radicals together form a —C(CH 3 ) 2 —C(CH 3 ) 2 — bridge, 
           and 
           X 3  represents bromine or iodine, 
           to give a compound of the formula (I-D) 
         
       
       
         
           
           
               
               
           
         
         
           in which n, L, R 1 , R 2 , R 3 , R 4  and R 5A  each have the meanings given above, 
           or 
           [E] reacting a compound of the formula (V) with a compound of the formula (XVI)
   R 25 —Y  (XVI)
 
 
           in which R 25  represents 4-methoxybenzyl (PMB) or trimethylsilylethyloxymethyl (SEM) 
           and 
           Y represents chlorine, 
           in an inert solvent in the presence of a suitable base to produce a compound of the formula (XVII) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4 , X 1  and R 25  have the meanings given above, 
           and then in an inert solvent in the presence of a suitable transition metal catalyst with a compound of the formula (XV-A), (XV-B), (XV-C) or (XV-D) 
         
       
       
         
           
           
               
               
           
         
         
           in which 
           R 5A  in (XV-A) represents (C 2 -C 4 )-alkenyl or (C 2 -C 4 )-alkynyl, 
           R 5A  in (XV-B), (XV-C) and (XV-D) represents halogen, difluoromethyl, trifluoromethyl, (C 1 -C 4 )-alkyl, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl, cyclopropyl, cyclobutyl, phenyl or 5- or 6-membered heteroaryl,
 in which (C 1 -C 6 )-alkyl, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl, phenyl and 5- or 6-membered heteroaryl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of cyano, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 4 )-alkyl, difluoromethoxy, trifluoromethoxy, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkoxycarbonyl, hydroxy, hydroxycarbonyl, cyclopropyl and cyclobutyl, 
 
           T 2  is hydrogen or (C 1 -C 4 )-alkyl, or both R 11  radicals together form a —C(CH 3 ) 2 —C(CH 3 ) 2 — bridge, 
           and 
           X 3  represents bromine or iodine, 
           to give a compound of the formula (XVIII) 
         
       
       
         
           
           
               
               
           
         
         
           in which n, L, R 1 , R 2 , R 3 , R 4 , R 5A  and R 25  each have the meanings given above, 
           and from this the PMB protective group is removed by reaction with a mixture of trifluoromethanesulphonic anhydride and trifluoroacetic acid or trifluoroacetic acid and trifluoromethanesulphonic acid or cerium(IV) ammonium nitrate and the SEM protective group by reaction initially with trifluoroacetic acid and then with aqueous mineral acid in suitable solvents, 
           or 
           [F] reacting a compound of the formula (XVII) is with a compound of the formula (XIX) 
         
       
       
         
           
           
               
               
           
         
         
           in an inert solvent in the presence of a suitable base to produce a compound of the formula (XX) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3 , R 4  and R 25  have the meanings given above and 
           R 26  and R 27  independently of one another represent cyano or (C 1 -C 4 ) alkoxycarbonyl, 
           and removing the protective group R 25  from the compound of formula (XX), as described in [E], where by hydrolysis and decarboxylation compound (1-E) is formed 
         
       
       
         
           
           
               
               
           
         
         or 
         [G] reacting a compound of the formula (V) with CuCN in an inert solvent to produce a compound (XXI)
 in which L, R 1 , R 2 , R 3  and R 4  have the meanings mentioned above 
 
       
       
         
           
           
               
               
           
         
         
           converting the compound of formula (XXI) by hydrogenation according to customary known methods into an amine of the formula (1-F) 
         
       
       
         
           
           
               
               
           
         
         
           in which L, R 1 , R 2 , R 3  and R 4  have the meanings mentioned above, 
           reacting the compound of formula (1-F) in an inert solvent in the presence of a suitable base with a compound of the formula (XXII)
   R 14′ —X 1   (XXII)
 
 
           in which R 14′  has the meanings mentioned above for R 14 , with the exception that R 14′  may not represent hydrogen, 
           X 1  represents a suitable leaving group, in particular chlorine, bromine, iodine, mesylate, triflate or tosylate, to give a compound of the formula (1-G) 
         
       
       
         
           
           
               
               
           
         
         and, optionally converting the resulting compounds of the formulae (I-A), (I-B), (I-C) I-D), (I-E), (I-D) and (I-G) with a (i) solvent and/or (ii) acid or base into a salt thereof. 
       
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . A pharmaceutical composition comprising a compound of  claim 1  and an inert, non-toxic, pharmaceutically suitable excipient. 
     
     
         13 . A pharmaceutical composition comprising a compound of the  claim 1  and an active compound selected from the group consisting of an organic nitrate, an NO donor, a cGMP-PDE inhibitor, an antithrombotic agent, a hypotensive agent and a lipid metabolism modifier. 
     
     
         14 . (canceled) 
     
     
         15 . A method for the treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, thromboembolic disorders and arteriosclerosis comprising administering an effective amount of at least one compound of  claim 1  to a human or animal in need thereof. 
     
     
         16 . A method for the treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, thromboembolic disorders and arteriosclerosis comprising administering an effective amount of at least one pharmaceutical composition of  claim 12  to a human or animal in need thereof.